Phase III Trial of High-dose Melphalan and Stem Cell Transplantation Versus High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis

Trial Profile

Phase III Trial of High-dose Melphalan and Stem Cell Transplantation Versus High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Bortezomib (Primary) ; Melphalan
  • Indications Amyloid light-chain amyloidosis
  • Focus Therapeutic Use
  • Acronyms VelRand
  • Most Recent Events

    • 03 Jul 2017 Status changed from suspended to discontinued for toxicity evaluation.
    • 06 Jun 2016 Status changed from recruiting to suspended for toxicity evaluation.
    • 07 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top